Gut peptide receptor expression in human pancreatic cancers

Annals of Surgery

Volumn 231, Issue 6, 2000, Pages 838-848

  Ehlers, Richard A ^a   Kim, Sung Hoon ^a   Zhang, Yujin ^a   Ethridge, Richard T ^a   Murrilo, Carlos ^a   Hellmich, Mark R ^a   Evans, Douglas B ^b   Townsend Jr , Courtney M ^a   Evers, B Mark ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTENSIN RECEPTOR; PEPTIDE;

ADENOCARCINOMA; ARTICLE; CANCER GROWTH; EARLY DIAGNOSIS; GASTRIN RELEASE; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR UPREGULATION;

ADENOCARCINOMA; HUMANS; PANCREATIC NEOPLASMS; RECEPTORS, BOMBESIN; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROPEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0034082312     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200006000-00008     Document Type: Article

References (46)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
2. Scheithauer W, Kornek GV, Raderer M, et al. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 1999; 80:1797-1802.
3. Royce ME, Pazdur R. Novel chemotherapeutic agents for gastrointestinal cancers. Curr Opin Oncol 1999; 11:299-304.
4. Green S, Furr B. Prospects for the treatment of endocrine-responsive tumours. Endocr Relat Cancer 1999; 6:349-371.
5. Townsend CM Jr, Singh P, Thompson JC. Hormonal effects on gastrointestinal cancer growth. In: Etievant C, Cros J, Rustum YM, eds. New Concepts in Cancer: Metastasis, Oncogenes and Growth Factors. London: MacMillan Press; 1990:208-217.
6. Townsend CM Jr, Bold RJ, Ishizuka J. Gastrointestinal hormones and cell proliferation. Surg Today 1994; 24:772-777.
7. Townsend CM Jr, Singh P, Evers BM, et al. Effect of gastrointestinal hormones on neoplastic growth. Chapter 21. In: Thompson JC, Cooper CW, Greeley GH Jr, et al, eds. Gastrointestinal Endocrinology: Receptors and Post-Receptor Mechanisms. San Diego: Academic Press; 1990:273-284.
8. Beauchamp RD, Townsend CM Jr, Singh P, et al. Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice. Ann Surg 1985; 202:303-309.
9. Singh P, Le S, Beauchamp RD, et al. Inhibition of pentagastrinstimulated up-regulation of gastrin receptors and growth of mouse colon tumor in vivo by proglumide, a gastrin receptor antagonist. Cancer Res 1987; 47:5000-5004.
10. Upp JR Jr, Singh P, Townsend CM Jr, Thompson JC. Predicting response to endocrine therapy in human pancreatic cancer with cholecystokinin receptors. Gastroenterology 1987; 92:1677.
11. Townsend CM Jr, Franklin RB, Watson LC, et al. Stimulation of pancreatic cancer growth by caerulein and secretin. Surg Forum 1981; 32:228-229.
12. Hirata M, Itoh M, Tsuchida A, et al. Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines. FEBS Lett 1996; 383:241-244.
13. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med 1999; 40:352-360.
14. Raderer M, Kurtaran A, Hejna M, et al. 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br J Cancer 1998; 78:1-5.
15. Raderer M, Kurtaran A, Yang Q, et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med 1998; 39:1570-1575.
16. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973; 248:6854-6861.
17. Polak JM, Sullivan SN, Bloom SR, et al. Specific localization of neurotensin to the N cell in human intestine by radioimmunoassay and immunocytochemistry. Nature 1977; 270:183-184.
18. Vita N, Laurent P, Lefort S. et al. Cloning and expression of a complementary DNA encoding a high-affinity human neurotensin receptor. FEBS Lett 1993; 317:139-142.
19. Tanaka K, Masu M, Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 1990; 4:847-854.
20. Sakamoto T, Newman J, Fujimura M, et al. Role of neurotensin in pancreatic secretion. Surgery 1984; 96:146-153.
21. Thor K, Rosell S. Neurotensin increases colonic motility. Gastroenterology 1986; 90:27-31.
22. Tasuta M, Iishi H, Baba M, Taniguchi H. Enhancement by neurotensin of experimental carcinogenesis induced in rat colon by azoxymethane. Br J Cancer 1990; 62:368-371.
23. Yoshinaga K, Evers BM, Izukura M, et al. Neurotensin stimulates growth of colon cancer. Surg Oncol 1992; 1:127-134.
24. Maoret JJ, Anini Y, Rouyer-Fessard C, et al. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999; 80:448-454.
25. Gully D, Canton M, Boigegrain R, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 1993; 90:65-69.
26. Iwase K, Evers BM, Hellmich MR, et al. Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surg Oncol 1996; 5:245-251.
27. Maoret JJ, Pospai D, Rouyer-Fessard C, et al. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun 1994; 203:465-471.
28. Ehlers RA, II, Bonnor RM, Wang X, et al. Signal transduction mechanisms in neurotensin-mediated cellular regulation. Surgery 1998; 124:239-246.
29. Ishizuka J, Townsend CM Jr, Thompson JC. Neurotensin regulates growth of human pancreatic cancer. Ann Surg 1993; 217:439-445.
30. Iwase K, Evers BM, Hellmich MR, et al. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer 1997; 79:1787-1793.
31. Reubi JC, Waser B, Friess H, et al. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998; 42: 546-550.
32. Rosewicz S, Ahnert-Hilger G, Haller H, et al. Rat pancreatic AR42J cells. Amphicrine cells as an in vitro model to study peptide hormone receptor regulation. Ann NY Acad Sci 1994; 733:407-415.
33. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995; 36:1846-1853.
34. Damge C, Hajri A. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol 1998; 347:77-86.
35. Goode T, O'Connell J, Sternini C, et al. Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononuclear cells: molecular quantitation and localization. J Immunol 1998; 161: 2232-2240.
36. Bruns CJ, Harbison MT, Kuniyasu H, et al. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999; 1:50-62.
37. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
38. Mehra M. RNA isolation from cells and tissues. In: Krieg PA, ed. A Laboratory Guide to RNA; Isolation, Analysis, and Synthesis. New York: Wiley-Liss; 1996:1-20.
39. Evers BM, Zhou Z, Celano P, Li J. The neurotensin gene is a downstream target for Ras activation. J Clin Invest 1990; 95:2822-2830.
40. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260:3440-3450.
41. Herzig MC, Chapman WG, Sheridan A, et al. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692. Anticancer Res 1999; 19:213-219.
42. Fisher WE, Muscarella P, Boros LG, Schirmer WJ. Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma. Int J Pancreatol 1998; 24:169-180.
43. Yamada M, Ohata H, Momose K, Richelson E. Pharmacological characterization of SR 48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2. Res Commun Mol Pathol Pharmacol 1995; 90:37-47.
44. Greeley GH Jr, Newman J. Enteric bombesin-like peptides. In: Thompson JC, Greeley GH Jr, Rayford PL, Townsend CM Jr, eds. Gastrointestinal Endocrinology. New York: McGraw-Hill; 1987:322-332.
45. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12:450-482.
46. van Eijck CH, de Jong M, Breeman WA, et al. Somatostatin receptor imaging and therapy of pancreatic endocrine tumors. Ann Oncol 1999; 10:177-181.